We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex) to treat myeloma patients on National Health Service (NHS) Scotland.
The UK National Institute for Health and Care Excellence (NICE) has issued a second draft ‘no’ on Takeda’s Ninlaro (ixazomib) for the treatment of patients with relapsed or refractory myeloma.